Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Peer Review reports

From: Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease

Original Submission
4 Mar 2024 Submitted Original manuscript
26 Mar 2024 Author responded Author comments - Rohit Aggarwal
27 Mar 2024 Author responded Author comments - Rohit Aggarwal
Resubmission - Version 2
26 Mar 2024 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
3 Jun 2024 Reviewed Reviewer Report
15 Jul 2024 Reviewed Reviewer Report - Chia-Hao Liang
18 Sep 2024 Author responded Author comments - Rohit Aggarwal
Resubmission - Version 4
18 Sep 2024 Submitted Manuscript version 4
Publishing
30 Sep 2024 Editorially accepted
30 Oct 2024 Article published 10.1186/s12890-024-03314-0

You can find further information about peer review here.

Back to article page